Compare IKT & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | INGN |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.3M | 190.9M |
| IPO Year | 2020 | 2014 |
| Metric | IKT | INGN |
|---|---|---|
| Price | $1.69 | $6.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 704.4K | 186.5K |
| Earning Date | 11-14-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $347,028,000.00 |
| Revenue This Year | N/A | $8.04 |
| Revenue Next Year | N/A | $8.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.68 |
| 52 Week Low | $1.33 | $5.70 |
| 52 Week High | $3.32 | $12.91 |
| Indicator | IKT | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 42.67 |
| Support Level | $1.63 | $6.00 |
| Resistance Level | $1.73 | $7.46 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 17.29 | 32.88 |
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.